Fri, Sep 19, 2014, 10:01 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • rubinstein.arno rubinstein.arno Jul 17, 2013 10:45 AM Flag

    OGXI-DD // 3 Blockbusters in Phase 3 Partnered with Teva Pharma // First Results in 4Q and 1Q 2014

    OGXI is an undiscovered Cancer Play with a Mega BLOCKBUSTER Pipeline ( 3x Phase 3 partnered with Pharma giant TEVA Pharma and another 6 candidates in Phase 2 ) .

    They have enough Cash untill late 2015 and a very Low Float of only 11 M shares .

    OncoGenex (OGXI)

    Market-Cap: $149 M
    Cash: $65 M
    NO Debt

    Shares Out : 14.7 M
    Fully Diluted : 17.7 M

    Emerging Leader in Next Generation Cancer Therapeutics

    Novel therapeutics that address mechanisms of treatment resistance in cancer

    Solid pipeline across multiple indications

    Custirsen in three Phase 3 trials

    SYNERGY prostate cancer death events for final analysis expected
    Q4 2013; data results expected to be announced H1 2014

    OGX-427 in seven randomized Phase 2 trials in four tumor types
    Key clinical catalysts across multiple late-stage programs:
    2013–2015

    Strong financial profile supports pipeline through 2015

    $64.6M in cash and investment securities as of 3/31/13

    Teva to fund all remaining custirsen expenses

    Custirsen

    Prostate Cancer
    Combination with 1st line chemotherapy (SYNERGY) in Phase 3 Teva partnership

    Combination with 2nd line chemotherapy (AFFINITY) in Phase 3 Teva partnership

    Non-Small Cell Lung Cancer
    Combination with 2nd line chemotherapy (ENSPIRIT) in Phase 3 Teva partnership

    OGX-427
    Unpartnered product candidate

    Bladder Cancer
    Superficial/muscle-invasive in Phase 1

    Combination with 1st Line Chemo (metastatic)(Borealis-1™) in Phase 2

    Combination with 2nd Line Chemo (metastatic)(Borealis-2™) in Phase 2

    Non-squamous non–small cell lung cancer
    Combination with 1st line chemotherapy (advanced)(Spruce™) in Phase 2

    Squamous non–small cell lung cancer
    Combination with 1st line chemotherapy (advanced) (Cedar™) in Phase 2

    Pancreatic cancer
    Combination with 1st line chemotherapy (metastatic) (Rainer™) in Phase 2

    Prostate Cancer
    Combination with prednisone (pre-chemo) in Phase 2
    Combination with abiraterone acetate (pre- or post-chemo) (Pacific™) in Phase 1

    OGX-225
    Solid Tumors in P

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OGXI
2.80-0.20(-6.67%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.